On one hand, we should continue developing agonists/antagonists with higher specificity
Some may even carry risks without delivering meaningful benefits
I have been using the now discontinued gel for YEARS, it was a staple in my morning routine especially in the summer months
placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD
In this week's Drugstore Cowboy, I explore why conflicts of interest matter just as much as scientific evidence, and why institutions have an obligation not only to be impartial, but to appear impartial